You are here
Dr Marc Seal
Dr Seal trained as a clinical neuropsychologist and has over 12 years experience in coordinating neuroimaging investigations of brain development. After completing his PhD he was awarded a Wellcome Trust International Fellowship (2001-2002) to support a two-year postdoctoral position in the Section of Neuroimaging, Institute of Psychiatry(IOP), Kings College London. Subsequently, Dr Seal was able to obtain a NARSAD Young Investigator Award (2003-2005) to continue his postdoctoral training in neuroimaging. In 2005 Dr Seal returned to Australia as a member of the Senior Research Group at The Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne. In this position he coordinated several large investigations measuring changes in brain structure and function across the life-span. On the basis of this work he was awarded the Ronald Phillip Griffith Fellowship (2007-2009). From 2007-2010 he successfully coordinated onsite Australia’s largest study investigating the neurocognitive impact of heavy cannabis use on brain development (NHMRC Project 459111). In 2010 he was was appointed Group Leader of the Developmental Imaging research group at the Murdoch Childrens Research Institute.
In this role he is responsible for coordinating and facilitating research utilising the Research MRI Scanner and supervises a multidisciplinary team of clinicians, MRI technologists and neuroscientists. He is currently involved in several ongoing studies of neurodevelopment including as Chief Investigator on NHMRC Project Grants and ARC Discovery Grants. He holds a joint appointment (0.5) as a Senior Research Fellow in the Department of Paediatrics, The University of Melbourne.
Ronald Phillip Griffith Fellowship, The University of Melbourne, 2007 - 2009
NARSAD Young Investigator Award, NARSAD, 2004 - 2005
Wellcome Trust International Research Fellow, The Wellcome Trust, 2002 - 2003
SIRS Travel Award, SIRS, 2010
Brain Travel Grant, Brain, 2004
NIH Postgraduate Travel Award, NIH, 2000
Australian Postgraduate Award (APA), Australian Federal Government, 1995 -1997
Dr Seal has a long-standing interest in neurodevelopment and cognitive neuroscience. His research focus is understanding childhood development and health through the use of sophisticated medical imaging acquisition and analysis techniques (MRI).
His ultimate goal is to actively translate our findings and innovations into improved diagnostic and therapeutic care for children & adolescents.
- Understanding Typical Brain development in Melbourne Children (SPROUT)
- Families And Childhood Transitions Study (FACTS)
- Childhood to Adolescence Transition Study - Neuroimaging Component (iCATS)
- Neurobiological consequences of Type I Diabetes in Adolescence
Adamson C, Anderson V, Nopolous P, Seal, ML, Da Costa, A. (2014) Regional Brain Morphometric Characteristics of nonsyndromic cleft lip and palate. Developmental Neuroscience. 36(6),490-498.
Cheong JLY, Anderson PJ, Roberts G, Burnett AC, Lee KJ, Thompson DK, Molloy C, Wilson-Ching M, Connelly A, Seal ML, Wood SJ, Doyle LW. (2013) Contribution of brain size to IQ and educational underperformance in extremely preterm adolescents. PLOS ONE [Volume 8, Issue 10, 9 October 2013, Article number e77475
Atakan Z, Bhattacharyya S, Allen P, Martín-Santos R, Crippa JA, Borgwardt SJ, Fusar-Poli P, Seal M, Sallis H, Stahl D, Zuardi AW, Rubia K, McGuire P (2103). Cannabis affects people differently: inter-subject variation in the psychotogenic effects of ?9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers. Psychological Medicine, 43 ( 6 ) pp. 1255 - 1267 .
Zalesky A, Solowij N, Yücel M, Lubman D, Takagi M, Harding I, Lorenzetti V, Wang R, McGuire P, Pantelis C, Searle K, Seal ML (2012). Effect of Long-term Cannabis Use on Axonal Fiber Connectivity. Brain, 135(7), 2245-2255.
Bhattacharyya S, Crippa JA, Allen P, Martin-Santos R, Borgwardt S, Fusar-Pol P, Rubia K, Kambeitz J, O’ Carroll CM, Seal M, Giampietro V, Brammer M, Zuardi AW, Atakan Z, McGuire P. (2012). Induction of psychosis by Delta-9-Tetrahydrocannabinol reflect modulation of prefrontal and striatal function during attentional salience processing. Archives of General Psychiatry, 69(1):27-36.
Nelson, MT, Seal ML, Phillips LJ, Merritt AH, Wilson R, Pantelis C. (2011) An investigation of the relationship between cortical connectivity and schizotypy in the general population. Journal of Nervous and Mental Disease, 199(5):348-353.
Winton-Brown TT, Allen P, Bhattacharrya S, Borgwardt SJ, Fusar-Poli P, Crippa JA, Seal ML, Martin-Santos R, Ffytche D, Zuardi AW, Atakan Z, McGuire PK (2011). Modulation of auditory and visual processing by delta-9- tetrahydrocannabinol and cannabidiol: An fMRI study. Neuropsychopharmacology, 36(7): 1340-1348.
Zalesky A, Fornito A, Seal ML, Cocchi L, Westin C.-F, Bullmore, ET, Egan GF, Pantelis C. (2011). Disrupted axonal fiber connectivity in schizophrenia. Biological Psychiatry, 69(1):80-89.
Wood SJ, Kennedy D, Phillips LJ, Seal ML, Yücel M, Nelson B, Yung AR, Jackson G, McGorry PD, Velakoulis D, Pantelis C. (2010). Hippocampal pathology in individuals at ultra-high risk for psychosis: A multi-modal magnetic resonance study. NeuroImage, 52(1):62-68.
Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, O'Carroll CM, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire PK. (2010). Opposite effects of d-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology, 35(3):764-774.
- National Health Medical Research Council (NHMRC)
- Australian Research Council (ARC)
- Royal Children’s Hospital Foundation
- National Stroke Foundation
- Juvenile Diabetes Research Foundation